Verrica To Share Phase 2 Results for VP-315 in BCC Treatment at Fall Clinical
Verrica Pharmaceuticals announced today that two abstracts featuring positive topline results from their phase 2 study of VP-315 for the treatment of basal cell carcinoma (BCC) will be presented at the 2024 Fall Clinical Dermatology Conference.
The presentations will focus on safety, tolerability, and histological clearance data for VP-315, an oncolytic peptide therapy designed to be administered directly into the tumor. VP-315, according to the manufacturer, is a first-in-class oncolytic chemotherapeutic peptide immunotherapy aimed at inducing immunogenic cell death, offering a non-surgical alternative to current BCC treatment options. In Part 2 of the phase 2 trial for VP-315, 82 patients with up to two BCC tumors each were treated; preliminary results indicate 51% of the tumors achieved complete histological clearance, with 71% average reduction in tumor size for those with residual tumors. No treatment-related serious adverse events were reported. Most adverse events were mild to moderate.
“We believe the positive preliminary topline results from Part 2 of the Phase 2 study for VP-315 are a meaningful step forward in potentially providing BCC patients with additional treatment options,” said Ted White, President and Chief Executive Officer of Verrica, said in a news release. “We are encouraged by our preliminary results, which we believe support the use of VP-315 as a first line therapy for use in both primary, and neoadjuvant settings. As a novel oncolytic peptide administered directly into the tumor, VP-315 has the potential to offer a non-surgical alternative for the three to four million cases of BCC diagnosed in the U.S. each year, representing a multi-billion-dollar commercial opportunity for Verrica.”
Source: Verrica Pharmaceuticals press release. October 24, 2024.